Compare OLOX & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLOX | VBIO |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4M | 1.6M |
| IPO Year | 2011 | 2021 |
| Metric | OLOX | VBIO |
|---|---|---|
| Price | $0.88 | $2.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.3M | ★ 23.1M |
| Earning Date | 06-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,952,578.00 | $780,000.00 |
| Revenue This Year | $1,628.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.11 |
| 52 Week High | $11.40 | $4.14 |
| Indicator | OLOX | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 17.89 | 55.54 |
| Support Level | $0.58 | $0.30 |
| Resistance Level | $1.14 | $4.14 |
| Average True Range (ATR) | 0.26 | 0.59 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 3.40 | 51.91 |
Olenox Industries Inc provides modular structures made from code-engineered cargo shipping containers as permanent or temporary structures for residential housing, commercial structures, and industrial applications. Its segments are: Construction, Software-as-a-Service (SaaS), Oil and Gas, and Others. Construction segment generates maximum revenue and designs and constructs modular structures in its factory using recycled shipping containers; in the past, traditional wood and steel frames were also used. It markets its construction products to contractors, home builders, building owners, other resellers, large multinational corporations, government agencies, private developers, the U.S. Military, individual homeowners, and pop-up retailers across the continental United States and Canada.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.